What happens when patients come off GLP-1s?

How much weight comes back after stopping?

Most of it, within about a year and a half. That is the consistent finding from the three studies that now set the benchmark, and it holds for semaglutide and tirzepatide alike.

The STEP 1 extension, published in Diabetes, Obesity and Metabolism in 2022, followed 327 people for a year after they stopped treatment. Those on semaglutide 2.4 mg had lost a mean 17.3% of their body weight at week 68. By week 120 they had regained 11.6 percentage points, about two-thirds of the loss. The improvements in blood pressure and lipids drifted back towards baseline at the same time.

SURMOUNT-4, published in JAMA, is the tirzepatide equivalent. After a 36-week lead-in in which participants lost a mean 20.9%, 670 people were randomised to continue tirzepatide or switch to placebo. Over the next 52 weeks the placebo group regained 14.0% of body weight while the tirzepatide group lost a further 5.5%. Only 16.6% of the placebo group kept at least 80% of their lead-in loss, against 89.5% of those still on the drug.

The Oxford group's systematic review in the BMJ on 7 January 2026 pooled 37 studies and 9,341 participants across every licensed weight-loss medicine. The table below summarises the three sources.

The BMJ authors made one further point that matters for service design. Regain after stopping medication was nearly four times faster than after a behavioural programme ended. Their conclusion was blunt: the drugs alone may not be enough for long-term weight control.

Why are so many patients stopping now?

Because the market is large, treatment is expensive, and some pathways have a built-in end date. A UCL survey study in BMC Medicine, reported on 8 January 2026, estimated that 1.6 million adults in Great Britain had used a weight-loss drug in the year to March 2025. A further 3.3 million said they were interested. Use was twice as common in women (4%) as in men (1.7%).

That is many times the NHS's own ambition. NHS England's interim commissioning guidance for tirzepatide, updated on 2 April 2026, plans for about 220,000 people in primary care over the first three years. So most patients are private, and most private patients pay by the month. Wegovy and Mounjaro have been on the UK private market for more than two years. The first large cohorts have reached the point where cost, side effects or a target weight prompt a stop.

Price is the biggest single reason. Lilly's list price increase took effect on 1 September 2025. The Pharmaceutical Journal reported the new list prices on 18 August 2025: £133 for the 2.5 mg pen and £330 for the 12.5 mg and 15 mg pens. The old range was £92 to £122. Some pharmacies froze their retail prices and Lilly offered rebates, but for a self-paying patient the monthly bill still decides how long treatment lasts.

Two rules add an end date on the NHS side. NICE's semaglutide appraisal, TA875, limits Wegovy to two years within a specialist weight-management service. Tirzepatide has no maximum duration under TA1026. But NICE NG246 says the prescriber should decide whether to continue if less than 5% of starting weight has gone after six months on the highest tolerated dose. Both rules create patients who stop while still needing help.

Parliament has noticed where those patients go. On 25 March 2026 the Health and Social Care Committee heard Boots's superintendent pharmacist, Claire Nevinson, describe community pharmacy as "perfectly placed" to deliver a nationally commissioned weight-management service. The MHRA's Andy Morling told the same session that about 81,000 GLP-1 doses had been seized over three years. He put seizures at no more than 5 to 10% of the illegal market. The demand does not vanish when a prescription ends; it moves.

What NICE and NHS England expect after the last dose

A year of structured follow-up. NICE published quality standard QS212 on 5 August 2025. Statement 7 says people who are stopping medicines for weight management should be given advice for maintaining changes and support for improving their health and wellbeing. The definitions are specific. Advice includes feedback and monitoring at regular intervals for a minimum of one year. It also includes well-rehearsed if-then plans for weight fluctuations, and a range of follow-up options once the active phase ends.

The underlying guideline, NG246 (14 January 2025), says the same in fewer words: offer support to help maintain weight loss to people who are stopping weight-management medicines. NICE's practical guide on tirzepatide adds that without a continued reduced-calorie diet and increased physical activity, stopping is likely to lead to weight regain. It does not specify a taper.

NHS England's wraparound-care guidance for tirzepatide in primary care was published on 5 January 2026. It describes what NHS patients get: monthly titration and monitoring appointments, a behavioural programme delivered over nine consecutive months, and shared decision-making on when and how to stop. Its interim commissioning guidance, updated on 2 April 2026, says deprescribing should come with advice for maintaining changes in line with QS212.

When QS212 appeared, the pharmacy bodies claimed the territory. The NPA's Henry Gregg said pharmacies take seriously their responsibility to provide full wraparound support. The CCA's Malcolm Harrison said pharmacies are well placed to provide a wraparound weight-loss care service. Both quotes were reported by The Pharmaceutical Journal on 5 August 2025. What neither body has published since is a service specification, a fee or an outcome measure for the year after treatment ends.

Does tapering work?

Nobody knows for certain, and you should say so to patients. Neither the Mounjaro SmPC nor the Wegovy SmPC describes a taper. Mounjaro lists 2.5 mg as a starting dose and 5 mg, 10 mg and 15 mg as maintenance doses, with dose increases in 2.5 mg steps at least four weeks apart. Wegovy reaches its 2.4 mg maintenance dose over 16 weeks and allows a step back to the previous dose if gastrointestinal symptoms are significant. A planned step-down to zero is a prescriber's clinical decision, not a licensed schedule.

The best-known tapering data is observational. Embla, a digital clinic operating in Copenhagen and London, presented results at the European Congress on Obesity in May 2024. Of 2,246 patients, 353 reduced their semaglutide dose to zero over about nine weeks while receiving diet and exercise coaching. They lost a further 2.1% during the taper, and the 85 patients with 26-week follow-up data held a stable weight. That is a small, self-selected group with no control arm. It is a hypothesis, not a protocol.

The mechanism argues for caution. Commenting on the BMJ review, Professor Jason Halford of the University of Leeds said discontinuation brings an appetite rebound: more hunger, less satiety and stronger cravings. Professor John Wilding of the University of Liverpool, who led STEP 1, said obesity is a chronic disease that usually relapses when treatment stops. A taper may soften the rebound. It does not remove it.

Is low-dose maintenance allowed?

For tirzepatide at 5 mg, yes, and there is now trial evidence behind it. SURMOUNT-MAINTAIN was published online in The Lancet on 12 May 2026 and presented at the European Congress on Obesity in Istanbul the next day. After a 60-week open-label weight-loss phase, 378 US adults who had lost at least 5% were randomised for 52 weeks. The arms were the maximum tolerated dose (10 mg or 15 mg), 5 mg, or placebo.

The 5 mg arm kept most of the benefit at a third of the top dose. That matters commercially because 5 mg is a licensed maintenance dose in the Mounjaro SmPC. A patient stepping down from 15 mg to 5 mg stays within the licence, and pays for a cheaper pen.

Go lower and you are off-label. Keeping a patient on the 2.5 mg starting pen, or on semaglutide below 2.4 mg, is not covered by either SmPC. That is lawful, but only under conditions. The GPhC's In practice guidance for pharmacist prescribers was updated in April 2025. It says the prescriber must be satisfied there is sufficient evidence and experience of safety and effectiveness, and must document the reasoning. The GMC's prescribing guidance sets the same tests for doctors in paragraphs 102 to 108: enough evidence, an informed patient and a recorded rationale. Social-media "microdosing" is not evidence. SURMOUNT-MAINTAIN is, but only for 5 mg tirzepatide.

What a pharmacy maintenance service looks like

A 12-month programme of reviews built around QS212, with or without a medicine. The clinical content is not exotic. What is missing in most pharmacies is the structure: a booked schedule, defined measurements and written triggers for action. A service that supplies no medicine needs no prescriber. One that includes a taper or a 5 mg maintenance dose needs a pharmacist independent prescriber or a clinic partner. Our guide to setting up a weight-management clinic covers both routes.

The three-month point is where the evidence says to concentrate effort. The BMJ analysis found regain roughly linear at 0.4 kg a month on average, but SURMOUNT-4 shows the placebo curve steepest in the first weeks after withdrawal. Front-loading reviews costs little and catches the patients who need to restart early.

Verification, monitoring and records

The same rules that govern starting a GLP-1 govern stopping one. The GPhC's February 2025 guidance on pharmacy services at a distance says the prescriber must independently verify weight, height or BMI for weight-management medicines. A phone call is not an appropriate way to do it. It also says the prescriber must make sure the necessary monitoring arrangements are in place before prescribing. A step-down or maintenance prescription is a prescription, so those duties apply in full; see our summary of the verification duties.

The GPhC's updated inspection framework, published on 13 January 2026, tells inspectors to look at weight-loss services specifically. A maintenance service gives you the evidence they ask for: a monitoring plan, measured outcomes and a record of what happened when a patient regained. Keep the PMR entry for each review, including the measurements, the advice given and the next booked date. The GMC's guidance, paragraphs 92 to 96, expects the prescriber to review and monitor ongoing treatment. The GPhC's prescriber guidance asks pharmacists to decide what monitoring follows each prescribing decision, and to safety-net.

Is there money in it?

Yes, but not from the pens. There is no published UK data on maintenance-service revenue, so treat any forecast as an estimate. What can be said is structural. A patient on tirzepatide spends hundreds of pounds a month with you and then, on the day they stop, spends nothing. A paid review programme replaces part of that income with consultation fees. The margin is higher, and there is none of the price volatility described in our analysis of whether the weight-management boom is sustainable.

The second return is retention. The BMJ figures imply that a large share of leavers will be back at their starting weight within two years. A patient who was reviewed every quarter, and who trusts the pharmacy that reviewed them, restarts with you. One who left with a final pen and no follow-up restarts with whoever is cheapest on the day, or with an illegal seller. Oral GLP-1s will widen the choice further, as we discuss in what the Wegovy pill means for pharmacy.

The third return is regulatory. Weight-loss supply is where the GPhC is concentrating its attention. A documented maintenance pathway is the clearest answer to the question of what happens to your patients after the last prescription. Pharmacies that want NHS work should note that NHS England's pathway already includes nine months of behavioural support and monthly reviews. If a nationally commissioned pharmacy service follows, as pharmacy leaders urged the Committee in March, the pharmacies with a working maintenance model will be the ones ready to bid.

Key takeaways

FAQs